On February 11, 2019, Viridium Pacific Group Ltd. (“Viridium”), a TSXV-listed, consumer wellness and biotech innovation company, and the parent company of Experion Biotechnologies Inc., a Health Canada licensed producer of cannabis, completed the acquisition of EFX Laboratories Inc. (“EFX”), a private, Canadian biotech company focused on medical cannabis applications and treatments, by way of an amalgamation of EFX and a wholly-owned subsidiary of Viridium, in accordance with the Business Corporations Act (Alberta). As consideration for the acquisition of EFX, Viridium issued one common share of Viridium (a “Viridium Share”) for every 2.57 class A common voting shares of EFX resulting in the issuance of 49,412,781 Viridium Shares with an aggregate value of approximately $26.2 million.
Fasken advised EFX with a team that included Sarah Gingrich, William deJong and Kyle Cadieux.
